CFTR and cystic fibrosis: DMF can reinstate pro-inflammatory cytokine expression and ROS levels in CF cells bearing the most common mutation ΔF508 (both CFBE and HNE cells), and it restores TrikaftaTM efficacy, decreased due to the LPS effect, thus working in association with and addition to CFTR modulators [107].